key: cord-1025034-x7eoi1ay authors: Gök, Selim; Bahçecioğlu, Ömer Faruk; Durmuş, Mefküre; Gün, Zeynep Ülkü; Ersoy, Yasemin; Aytemur, Zeynep Ayfer; Ulutaş, Özkan title: The safety profile of favipiravir in COVID‐19 patients with severe renal impairment date: 2021-10-10 journal: Int J Clin Pract DOI: 10.1111/ijcp.14938 sha: 171df1048fddffc4b3b1e3cc706caefa658e14b5 doc_id: 1025034 cord_uid: x7eoi1ay OBJECTIVE: The safety profile of favipiravir in patients with severe renal impairment has not been investigated and available data are insufficient. The study aimed to compare the incidence of favipiravir‐associated adverse events amongst patients with varying renal function statuses. METHODS: Records of 921 patients who were hospitalised for COVID‐19 and had received at least 5 days of favipiravir treatment were retrospectively evaluated and 228 patients were included in the study. Patients’ age, sex, comorbidities, estimated glomerular filtration rate (eGFR) and haematological and biochemical values were recorded. The incidence of adverse events was compared with the age, sex, comorbidities and eGFR of the patients. RESULTS: The mean age of the patients was 59.3 ± 15.6 years, and 38.2% of the patients were women. One hundred and thirty‐one (57.5%) patients had experienced adverse events. These adverse effects consisted of ALT elevation (35.5%), AST elevation (21.5%), anaemia (16.2%), hyperuricaemia (10.5%), hepatocellular injury (9.2%), neutropenia (3.5%) and thrombocytopenia (2.6%). The incidence of adverse events was not significantly different when patients had eGFR >60 mL/min/1.73 m(2) or eGFR 30‐60 mL/min/1.73 m(2) (P > .05), but significantly increased when the eGFR dropped to <30 (P < .05). The differences seen with hyperuricaemia and anaemia were significant (P < .05). CONCLUSION: Even though favipiravir appeared to be well tolerated in the individuals with renal failure in this study, its use in this population remains a challenge that requires more research and analysis. the hydroxylated form via renal elimination. 3 Chronic kidney disease is frequently seen in the general population and is a risk factor for increased morbidity and mortality in COVID- 19 . The study aimed to compare the incidence of favipiravir-associated total and significant adverse events amongst patients having different estimated glomerular filtration rates (eGFRs). A retrospective observational study was conducted at Inonu University Turgut Ozal Medical Center between July 2020 and December 2020. Ethical approval for the study was granted by the Health Sciences Non-Interventional Ethics Committee of Inonu University (No: 2021/1541). Nine hundred and twenty-one patients with moderate to severe COVID-19 who had received favipiravir for at least five days participated in the study. Patients under the age of 18, patients who had received hydroxychloroquine or favipiravir before hospitalisation, patients using hydroxychloroquine and favipiravir concomitantly, patients who had received chemotherapy in the previous 3 weeks, patients with haematological disease and patients who had been treated in the intensive care unit at any stage of hospitalisation were excluded. Favipiravir was administered to all patients orally as a 2 × 1600 mg loading dose on the first day and 2 × 600 mg maintenance dose on the following days for a maximum of 14 days. The age, sex, comorbid diseases and eGFR levels (calculated via the CKD-EPI method) of the patients were evaluated. Biochemical and haematological parameters of patients who had received favipiravir were compared before and after treatment. The liver enzyme elevation grade, anaemia, neutropenia and thrombocytopenia were classified using the Common Terminology Criteria for Adverse Events (CTCAE v5.0). Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than the upper limit of normal (ULN) but <3 × ULN were considered grade-1 liver enzyme elevation. A 3-5-fold rise in AST or ALT compared with ULN was classified as grade 2, a 5-20-fold increase as grade 3 and a > 20-fold increase as grade 4. Normal ALT levels were identified as 19-25 IU/L for female patients and 29-33 IU/L for male patients, 4 whereas the normal AST levels were identified as 10-40 IU/L for female patients and 9-32 IU/L for male patients, and the normal alkaline phosphatase (ALP) levels were identified as 45-115 IU/L for male patients and 30-100 IU/L for female patients. Drug-induced liver injury (DILI) was classified as either hepatocellular, cholestatic or mixed-type on the basis of the ALT and the ALP levels. For example, the hepatocellular injury was defined as an ALT more than three times the ULN and an R value of >5, whereas the R value was calculated as (ALT/ULN)/(ALP/ULN). 5 The grade of anaemia was analysed as follows: grade 1 (male patient: 10.0-13.0 g/dL, female patient: 10.0-12.0 g/dL), grade 2 (male/ female patient: 8.0-10.0 g/dL) and grade 3 (male/female patient: <8.0 g/dL). The grade of neutropenia was set as follows: grade 1 (male/female patient: 1500-2100 µL), grade 2 (male/female patient: 1000-1500 µL), grade 3 (male/female patient: 500-1000 µL) and grade 4 (male/female patient: <500 µL). Moreover, the grade of thrombocytopenia was analysed as follows: grade 1 (male/female patient: 75 000-150 000 µL), grade 2 (male/female patient: 50 000-75 000 µL), grade 3 (male/female patient: 25 000-50 000 µL) and grade 4 (male/female patient: Favipiravir-associated hyperuricaemia was defined as a posttreatment serum uric acid value of >6 mg/dL. 6 The data were statistically evaluated using the SPSS 20.0 (Statistical Package for Social Sciences) software. The Shapiro-Wilk test was used for normality analysis, and parametric tests such as the independent sample t tests were used for quantitative data. Pearson's χ 2 test, Yates continuity correction, or Fischer's exact test were used to analyse the differences of the categorical data. A P value of <.05 was considered to be statistically significant. • In COVID-19 patients, chronic renal disease is linked to an increase in morbidity and mortality. • Despite the lack of safety data for favipiravir in patients with renal failure, the emergence of COVID-19 justifies its usage in this population. • Favipiravir-related side effects (eg, hepatocellular injury) are well known, although the risk factors that lead to these side effects are unknown. • Favipiravir increased the incidence of anaemia and hyperuricaemia in COVID-19 patients with severe renal impairment compared with those without renal impairment. However, these differences were not seen in severe adverse events (grades 3 and 4). • The hepatocellular injury seems to be durationdependent, as it was observed more frequently in patients treated with favipiravir for ≥10 days than in those treated for <10 days. Two hundred and twenty-eight COVID-19 patients receiving favipiravir therapy were included in this retrospective study. Baseline characteristic features of the patients receiving favipiravir are given in Table 1 . Approximately two-thirds of the patients had one or more comorbidities, with the most common comorbidity being hypertension. The patients were given favipiravir for a mean of 7.2 ± 2.4 days. One hundred and forty-two patients had normal renal function (eGFR >60 mL/min/1.73 m 2 ), 58 had moderate renal impairment (eGFR 30-60 mL/min/1.73 m 2 ) and 28 had severe renal impairment (eGFR <30 mL/min/1.73 m 2 ). Adverse events were seen in 131 (57.5%) COVID-19 patients after receiving favipiravir for an average of 6.5 ± 2.6 days. The observed adverse events included elevation of ALT and AST (35.5% and 21.5%, respectively), grades 1 and 2 anaemia (16.2%), hyperuricaemia (10.5%) and all grades of neutropenia (3.5%) and thrombocytopenia (2.6%). The mixed and cholestatic injury was not seen as DILI types, whereas the hepatocellular injury was seen in 9.2% of all patients. Although adverse events were observed in 61.3% of male patients and 51.2% of female patients (P = .135), ALT elevation was observed in 40.8% and 26.7% of male patients and female patients, respectively. The mean ages of those with and without adverse events were similar (P = .26). No association was found between the development of anaemia, thrombocytopenia, neutropenia, hyperuricaemia, ALT or AST elevation, hepatocellular injury or age (P > .05). Hypertension was found in 36.6% of male patients and 57% of female patients (P = .003). Diabetes mellitus was found in 25.4% of male patients and 45.3% of female patients (P = .002). The relationship between comorbidities and adverse events is given in Table 2 . Although the incidence of total adverse events in patients with at least one comorbidity and in those with no comorbidities seemed to be similar (P = .2), hyperuricaemia was observed more frequently in patients with at least one comorbidity (13.6% vs 4.1%, P = .048). Elevated levels of ALT were more common in non-diabetic subjects than in diabetics (P = .024), whereas AST elevation was higher in non-hypertensives than in hypertensives (P = .005). The incidence of favipiravir-associated adverse events in 142 patients with eGFR >60 mL/min/1.73 m 2 and in 58 patients with eGFR of 30-60 mL/min/1.73 m 2 was found to be similar (56.3% vs 48.3%, P = .299). The incidence of adverse events was 82.1% in patients with eGFR of <30 mL/min/1.73 m 2 , whereas it was 54% in patients with eGFR of >30 mL/min/1.73 m 2 (P = .008). Additionally, the rate of favipiravir-associated anaemia and hyperuricaemia was higher in the group with eGFR of <30 mL/min/1.73 m 2 (P < .05) ( Table 3) . Although the incidence of total adverse events was seen to be similar in patients who received favipiravir for ≥10 days and in those who received favipiravir for <10 days (P = .354), hepatocellular injury was observed more frequently in patients treated for ≥10 days (16.9% vs 5.7%, P = .014). have been found in more than 1% of individuals, pointing to probable DILI. 8 One trial demonstrated that patients with severe COVID-19 are predisposed to having abnormal liver function. 9 However, distinguishing between COVID-19-related liver injury and DILI is complicated. 10 In the present study, liver enzyme-related adverse effects were observed in patients at all grades of ALT (35.5%) and AST elevation (21.5%). Mixed-type and cholestatic-type DILI were not observed, whereas hepatocellular-type DILI was observed in 9.2% of all patients. Acute hepatocellular injury in 90% of toxicity cases has been reported in studies evaluating drug-induced hepatotoxicity with histopathological findings. 11 However, cases of cholestatic DILI developing after a 2-week favipiravir regimen have also been reported in the literature. In one of these cases, acute decompensation of cirrhosis with cholestatic jaundice was observed because of favipiravir In addition, one of the case reports showed that non-oliguric acute kidney injury had developed 48 hours after favipiravir treatment in two COVID-19 pneumonia patients with normal creatinine clearance at baseline. Acute kidney injury was resolved in these patients 24-48 hours after discontinuing favipiravir. 13 However, data associating-specific organ injury with favipiravir is limited. The decrease in the neutrophil count is a common haematological adverse event with favipiravir. 8 levels was greater in non-diabetic patients than in diabetic cases. Likewise, the elevation of AST levels was observed more frequently in patients without hypertension than in those with hypertension. The fact that adverse effects were more common in male patients than in female patients and that comorbidities such as diabetes and hypertension were less common in male patients than in female patients might be a contributory cause. Interestingly, patients without coronary artery disease had higher ALT enzyme levels than patients with coronary artery disease. As was expected, hyperuricaemia was more frequent in gout patients than in non-gout patients. The blood trough concentration of favipiravir in patients with moderate renal impairment had increased 1.5 times compared with that of patients with normal renal function. In addition, because of the lack of available data for severe renal impairment patients, some prescribing protocols consider favipiravir to be contraindicated in these patients. 19 Adverse events associated with the favipiravir treatment occurred in 43.4% of patients with mild renal insufficiency and in 30.3% of patients with normal creatinine clearance. Overall, the data are insufficient to recommend the use of favipiravir in patients with renal insufficiency. 10 In a study comparing the effect of chronic kidney disease on clinical and prognostic features amongst hospitalised COVID-19 patients, patients without chronic kidney disease were more commonly administered favipiravir than patients with chronic kidney disease. This problem was observed in this study and was associated with the lack of data on favipiravir use in the early pandemic period. In a study in which favipiravir was administered to a haemodialysis patient with COVID-19, the favipiravir blood concentrations were found to be similar to those of non-haemodialysis patients with normal renal function. 22 In another case report, no significant adverse events were observed in a patient on haemodialysis receiving favipiravir therapy, although serum ALP and gamma-glutamyl transferase levels increased during the treatment. 23 In this study, we looked at changes in laboratory values before and after favipiravir treatment for each patient independently. Anaemia and hyperuricaemia were more common in those with severe renal impairment than in the general population. Likewise, according to the findings of the current study, the incidence of anaemia and hyperuricaemia observed after favipiravir treatment in patients with severe renal impairment was higher than in the other groups. Therefore, regular follow-up monitoring of complete blood counts and biochemical parameters-particularly haemoglobin and uric acid-is needed in COVID-19 patients with severe renal impairment receiving favipiravir treatment. The single-centred, retrospective nature of the study may be con- In addition, another limitation of the study was that the longterm laboratory parameters of these patients were not assessed following favipiravir therapy. Favipiravir increased the incidence of anaemia and hyperuricaemia in COVID-19 patients with severe renal impairment. However, after the use of favipiravir, no increased incidence of significant adverse events (grades 3 and 4) was observed in COVID-19 patients with severe renal impairment compared with those without renal impairment. In conclusion, favipiravir appeared to be well tolerated in the renal failure patients in this study. Because there is a lack of information on favipiravir usage in patients with severe renal impairment, we believe that the findings of our study will contribute to the literature. However, favipiravir usage in this population remains a challenge that will require more research and investigation. None. There is no conflict of interest between authors. An update on current therapeutic drugs treating COVID-19 Favipiravir use in COVID-19: analysis of suspected adverse drug events reported in the WHO database Favipiravir: a new and emerging antiviral option in COVID-19 ACG clinical guideline: evaluation of abnormal liver chemistries Case definition and phenotype standardization in drug-induced liver injury Definition of hyperuricemia and gouty conditions Favipiravir versus arbidol for COVID-19: a randomized clinical trial Avigan Prescribing Information Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of retrospective studies Clinical features of COVID-19-related liver functional abnormality Histopathologic manifestations of drug-induced hepatotoxicity Favipiravirinduced liver injury in patients with coronavirus disease 2019 Favipiravir induced nephrotoxicity in two patients of COVID-19 The effects of favipiravir on hematological parameters of covıd-19 patients Treatment of SARS-cov-2 pneumonia with Favipiravir: early results from the Ege University cohort, Turkey Clinical characteristics of coronavirus disease 2019 in China A review of the safety of favipiravir-a potential treatment in the COVID-19 pandemic? Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis Unlocking the Treatment for Mild to Moderate COVID-19 in India COVID-19 in chronic kidney disease: a retrospective, propensity score-matched cohort study Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? Favipiravir for COVID-19 in a patient on hemodialysis Efficacy of favipiravir for an end stage renal disease patient on maintenance hemodialysis infected with novel coronavirus disease The safety profile of favipiravir in COVID-19 patients with severe renal impairment